The Spanish biopharmaceutical company Oryzon Genomics S.A., a global leader in the sector of epigenetics, has reached a strategic milestone in its internationalization and consolidation process in the North American market. United States Patent and Trademark Office (USPTO) has formally granted the patent US12,564,559 B2which protects the therapeutic combinations of iadademstat, the selective inhibitor of LSD1 developed by the firm.
This grant is critical to the company's global business, as the patent claims cover treatment methods for neoplastic diseases, specifically the AML (LMALegal protection includes a combination of iadademstat with venetoclax, which currently represents the first-line treatment standard for this pathology internationally.
Validity and commercial protection in the US market
The legal protection of this therapy will extend, according to current forecasts, until January 2039This period includes an adjustment of 681 days (PTAgranted by the US authority to compensate for administrative processing times. Furthermore, the validity period could be extended through possible extensions associated with future regulatory reviews of the drugs.
The following details the key information regarding the grant and the scope of the firm's intellectual property:
| Concept | Technical Details / Date |
|---|---|
| US Patent Number | US12,564,559 B2 |
| Expected expiration date | January 2039 |
| Lag Adjustment (PTA) | 681 days |
| Markets with patents obtained | Australia, Brasil, Canadá, Europa, India, Japón, México, among others. |
Clinical results: 100% efficacy in first-line treatment
The legal backing coincides with a phase of highly positive clinical results. Within the framework of the trial of Phase Ib called ALICE-2, Oryzon has evaluated the combination of its drug with venetoclax y azacitidinaThe data presented during the Congress of the American Society of Hematology (ASH) revealed exceptional effectiveness metrics:
- Overall response rate (ORR): 100%.
- Strict complete remission rate (CR): 90%.
- Recruitment status: Active and agile, with upcoming updates planned for June 2026.
“The granting of this patent in EE.UU. This represents a significant step forward for our growing patent portfolio for iadademstat”, Has stated Neus Virgili, Director of Patents of OryzonAccording to the directive, this step “provides protection until 2039, strengthening the long term value of our clinical programs.”
Global patent expansion and strategy
Beyond the US border, Oryzon Genomics S.A. It maintains a robust intellectual property strategy worldwide. The biotechnology company already holds patents for the combination of iadademstat with venetoclax in key markets such as Canadá, Europa, Brasil, Japón y CoreaIt also has additional protections for combinations with other agents such as the azacitidina and decitabina.
The company plans to present updated data from approximately 15–16 patients (75% of total recruitment) at the next congress of the European Hematology Association (EHA) which will be held in June 2026.
Key points and frequently asked questions about the Oryzon patent
How important is the combination with venetoclax?
It is fundamental because the venetoclax It is the current first-line standard of care for acute myeloid leukemia. Patenting its combined use with iadademstat It ensures commercial exclusivity for a potentially more effective therapy.
How long will technology be protected in the US?
The patent is valid until January 2039, guaranteeing almost 13 years of exclusive exploitation in the US market, a period that could be extended after the relevant regulatory reviews.
What clinical findings support this movement?
The studio ALICE-2 It has reported an overall response rate of 100% and a 90% complete remission rate in patients treated with the combination, which positions Oryzon in a privileged competitive position.
[
Any questions about this news?
Talk to Coexia, the AI of the foreign trade
